Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, in Tp53 deficient mice, Setd4 deletion did not delay the radiation-induced lymphomagenesis although it accelerated the spontaneous T-lymphomagenesis in non-irradiated mice.
|
31794893 |
2020 |
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our data demonstrates that ASPP2κ plays a distinctive role as an antiapoptotic regulator of the TP53 checkpoint, rendering cells to a more aggressive phenotype as evidenced by proliferation and apoptosis rates - and ASPP2κ expression results in acquisition of genomic mutations, a first initiating step in leukemogenesis.
|
30952616 |
2019 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
TP53 is a critical tumor suppressor and plays an essential role in leukemogenesis.
|
31289443 |
2019 |
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Further, TP53 mutations identified in CHIP cooperate with genetic and/or epigenetic changes in leukemogenesis.
|
31045645 |
2019 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we show that DNA damage response by p53 is a central mechanism suppressing the pathogenic cooperation of IKK2ca-enforced canonical NF-κB and impaired differentiation resulting from Blimp1 loss in ABC-DLBCL lymphomagenesis.
|
30975638 |
2019 |
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic Ablation of <i>Rbm38</i> Promotes Lymphomagenesis in the Context of Mutant p53 by Downregulating PTEN.
|
29330147 |
2018 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
On the contrary, when MDM2-ALT1 is expressed solely in B-cells in the presence of homozygous wild-type p53 it leads to significantly increased lymphomagenesis (56%) when compared with control mice (27%).
|
28892044 |
2018 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previous experimental work in mice revealed that T-cell specific deletion of Cdkn1c accelerates lymphomagenesis in the absence of Tp53.
|
29661169 |
2018 |
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We show that five TRP53 mutants do not accelerate lymphomagenesis on a TRP53-deficient background but strongly synergize with c-MYC overexpression in a manner that distinguishes the hot spot <i>Trp53</i> mutations.
|
30366906 |
2018 |
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results demonstrate that the level of p53 protein plays a crucial role in FA leukemogenesis.
|
29784053 |
2018 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Conversely, Ft1 reduction alters lymphomagenesis in p53 mutant mice.
|
29635765 |
2018 |
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Tumour analysis indicated that the selective pressure for mutation of the p53 pathway during Eμ-myc lymphomagenesis was not altered.
|
26764572 |
2016 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In a chromosomal instable p53 deficient mouse model with accelerated lymphomagenesis, we previously observed whole chromosome copy number changes affecting all lymphoma cells.
|
27246460 |
2016 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Intronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathway.
|
24736457 |
2014 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we show that tp53 mutations have no significant influence on the onset of myc-induced T-ALL in zebrafish, consistent with the lack of additional effects of Tp53 loss on lymphomagenesis in Arf-deficient mice.
|
24690081 |
2014 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, we provide evidence that in cell culture NS controls cell proliferation independently of p53 and that NS haploinsufficiency significantly delays lymphomagenesis in p53-deficient mice.
|
22081066 |
2012 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression of Fbxo7 in haematopoietic progenitor cells cooperates with p53 loss to promote lymphomagenesis.
|
21695055 |
2011 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using LMP2A transgenic mouse models, we have identified a novel mechanism that permits lymphomagenesis in the presence of an intact p53 pathway.
|
20160479 |
2010 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We further found that p53 acted as the dominant tumor suppressor during the onset of Emu-myc-driven B cell lymphomagenesis, while p73 modulated tumor dissemination and extranodal growth.
|
20484818 |
2010 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rac1 targeting suppresses p53 deficiency-mediated lymphomagenesis.
|
20179179 |
2010 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In both sets of models, the human or humanized p53 proteins are functional as evidenced by the transcriptional induction of p53 target genes in response to DNA damage and the suppression of early lymphomagenesis.
|
20587514 |
2010 |
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Epstein-Barr virus LMP2A bypasses p53 inactivation in a MYC model of lymphomagenesis.
|
19815507 |
2009 |
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
While the NF1 and TP53 TSGs follow the Knudson two-hit paradigm and undergo biallelic inactivation, there is increasing evidence that inactivation of a single allele of TSG such as RUNX1, PU.1 and RPS14 (haploinsufficiency) can also contribute to leukemogenesis.
|
19041599 |
2008 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we show that chloroquine, a drug that activates the stress-responsive Atm-p53 tumor-suppressor pathway, preferentially enhances the death of Myc oncogene-overexpressing primary mouse B cells and mouse embryonic fibroblasts (MEFs) and impairs Myc-induced lymphomagenesis in a transgenic mouse model of human Burkitt lymphoma.
|
18097482 |
2008 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Constitutive STAT5 activation specifically cooperates with the loss of p53 function in B-cell lymphomagenesis.
|
16532027 |
2006 |